```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable research compound extensively employed in platelet investigations. This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on platelets , inhibiting clot formation . As a result, it's often employed as a method to explore the pathways underlying thrombosis and to evaluate the efficacy of antiplatelet therapies. Distribution is typically controlled to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 and The 143653-53-6 Substance in Studies
Ongoing investigation into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antibody C7E3 and the chemical compound identified as 143653-53-6. These materials are instrumental for examining abciximab's mechanism of action, determining its efficacy in experimental conditions, and understanding potential biomarkers of treatment response. Continued study leveraging these 143653-53-6 particular reagents is expected to generate valuable insights for optimizing patient care concerning cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Potential Possibilities with Abciximab 143653-53-6 via C7E3
Recent research suggest that Abciximab (identified as 143653-53-6) offers significant scientific potential, particularly when paired with the antibody fragment. Early findings suggested that this combination might improve patient responses in several heart-related conditions. Further exploration is focused on defining the specific process of effect between the antiplatelet medication and C7E3, involving assessment of platelet aggregation and arterial protection.
- Current investigation efforts seek to optimize administration strategies.
- Preclinical models are were utilized to additional assess such hypotheses.
- Clinical trials are necessary to thoroughly evaluate clinical effectiveness.
```
Abciximab (C7E3) for Research: Purity and Characteristics (143653-53-6)
Researchers needing this antibody for in vitro research should meticulously assess purity and defined parameters . The compound is typically provided as a freeze-dried powder and comprehensive analytical documentation including verification by HPLC , potency assays, and bacterial endotoxin testing are available. Verify the manufacturer's certificate of analysis outlines defined limits for impurities and meets established QC standards .
High-Purity Abciximab Details & Supply
Acquiring laboratory-grade Abciximab, specifically referencing the molecule C7E3 and identified by the catalog number 143653-53-6, requires thorough consideration of its source . This agent is frequently utilized in in vitro studies , particularly those involving platelet adhesion and occlusion. Current suppliers offer this substance in varying volumes, typically ranging from milligram to significant bulk quantities . We suggest reviewing the report of quality to verify integrity and appropriateness for your specific purpose. Moreover, check the shelf life date before purchasing to maintain maximum efficacy .
- Typical Purity: >95%
- Preservation Conditions: -20°C and suitable conditions
- Application : Platelet Clumping Suppression Studies